Powder: -20°C for 3 years | In solvent: -80°C for 1 year
JNJ-49095397 (RV568) is a selective p38 MAPK-α and p38 MAPK--γ kinase inhibitor with anti-inflammatory activity and potential antiviral activity for chronic obstructive pulmonary disease (COPD), cystic fibrosis, and respiratory syncytial virus infection.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
1 mg | 在庫あり | ¥ 20,500 |
5 mg | 在庫あり | ¥ 49,000 |
10 mg | 在庫あり | ¥ 80,000 |
25 mg | 在庫あり | ¥ 159,500 |
50 mg | 約6-8 週間 | ¥ 250,500 |
説明 | JNJ-49095397 (RV568) is a selective p38 MAPK-α and p38 MAPK--γ kinase inhibitor with anti-inflammatory activity and potential antiviral activity for chronic obstructive pulmonary disease (COPD), cystic fibrosis, and respiratory syncytial virus infection. |
In vitro | JNJ-49095397 (1 μg-1 g/mL; 4 h) demonstrates potent anti-inflammatory effects in monocytes and macrophages. When used in combination with corticosteroids, it exhibits synergistic anti-inflammatory effects in poly I:C-stimulated BEAS-2B cells and cigarette smoke models[1]. |
In vivo | In non-fasted Balb/c mice, in the LPS-induced neutrophil accumulation model, JNJ-49095397 (1, 4, and 20 μg/mouse; intratracheal administration, 2, 8, or 12 h prior to LPS inhalation) prevented the accumulation of neutrophils in the BAL fluid. Significant inhibition of neutrophil accumulation was observed when administered up to 8 h prior to LPS inhalation[1]. |
別名 | RV568 |
分子量 | 592.69 |
分子式 | C34H36N6O4 |
CAS No. | 1220626-82-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 80 mg/mL (134.98 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
JNJ-49095397 1220626-82-3 Immunology/Inflammation MAPK Antiviral p38 MAPK RV-568 JNJ49095397 JNJ 49095397 RV568 RV 568 Inhibitor inhibitor inhibit